

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: PAPIEROK, Gérard; VICENS, Serge; LEMESRE, Jean-Loup

SERIAL NO.: 10/521,922

ART UNIT: 1645

FILED: August 29, 2005

EXAMINER: Gangle, B. J.

TITLE: SPECIFIC ISOTYPE ANTIBODIES OF SECRETION-EXCRETION ANTI-ANTIGENS OF *LEISHMANIA* *sp* OF PROMASTIGOTE OR AMASTIGOTE FORMS, etc...

Amendment A: CLAIM AMENDMENTS

Claims 1 - 9 (canceled). These claims are canceled by the present amendment.

10. (New) A composition for lysing amastigotes and promastigotes of *Leishmania* *sp* in vitro and for neutralizing proliferation of said amastigotes and promastigotes of *Leishmania* *sp*, said composition comprising:

immunoglobulins of IgG<sub>2</sub> and corresponding sub-classes, said immunoglobulins being specific to excretion-secretion antigens of said promastigotes or amastigotes of *Leishmania* *sp*., said immunoglobulins being specific to a major immunogen, belonging to Protein Surface Antigens and corresponding to a range of molecular mass from 52 to 58 kDa, said immunoglobulins being specific to a carboxyterminal part of said major immunogen, and said immunoglobulins being specific to isotypes IgG<sub>2</sub> in dogs and specific isotypes in other mammals, the isotypes being linked to cell-mediated immunity depending on T lymphocytes of the Th1 type.

11. (New) The composition of Claim 10, said immunoglobulins being markers for immunotherapy in leishmaniasis and infections by pathogenic intracellular micro-organisms in mammals.

12. (New) A method for using the composition of Claim 10, said method comprising the

steps of:

marking cell-mediated immunity by said immunoglobulins; and

detecting cell-mediated immunity depending on T lymphocytes and preferably T lymphocytes of the Th1 type in mammals.

13. (New) A method for using the composition of Claim 10, said method comprising the steps of:

marking resistance to leishmaniasis by said immunoglobulins; and

marking resistance to infections by pathogenic intracellular micro-organisms in mammals by said immunoglobulins.

14. (New) A method for using the composition of Claim 10, said method comprising the steps of:

marking immunoprophylactic and immunotherapeutic vaccination in mammals for leishmaniasis by said immunoglobulins; and

marking infections of pathogenic intracellular micro-organisms by said immunoglobulins.

15. (New) A method for using the composition of Claim 10 as an in vitro diagnostic product, said method comprising the steps of:

detecting one or more epitopes carried by terminal ends NH<sub>2</sub> and COOH of said Protein Surface Antigens excreted-secreted by *Leishmania sp.*